ABSTRACT
Immunotherapy has dramatically altered the treatment of non-small cell lung cancer. Currently, the emergence of combination strategies in immunotherapy has brightened the prospects of improved clinical outcomes and manageable safety profiles in the first/second-line settings. However, sub-optimal response rates are still observed in several clinical trials. Hence, alternative combination models and candidate selection strategies need to be explored. Herein, we have critically reviewed and commented on the published data from several clinical trials, including combined immunotherapy and chemotherapy, anti-angiogenic agents, epidermal growth factor receptor/anaplastic lymphoma kinase tyrosine kinase inhibitors, radiotherapy, and other immune checkpoint inhibitors.
Subject(s)
Humans , Angiogenesis Inhibitors/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Immunotherapy , Lung Neoplasms/drug therapy , Protein Kinase Inhibitors/therapeutic useABSTRACT
Pyroptosis is a novel programmed cell death mode mediated by inflammatory Caspase,which has a proinflammatory effect and is accompanied by cell membrane rupture and disintegration.In recent years,researchers found that the substrate of inflam-matory Caspase-Gasdermin D(GSDMD)protein,is the key"killer protein"to execute cell pyroptosis.The inflammatory Caspase spe-cifically cleaves the GSDMD protein,forming the N-terminal domain and the C-terminal domain,and eventually results in cell pyropto-sis by protein pores formation.This article focuses on the research progress of cell pyroptosis,the structural features of GSDMD protein, and the mechanism of GSDMD protein participating in the pyroptosis and the disease models.